Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acidic fibroblast growth factor combined with neurolysis for diabetic peripheral neuropathy
ChiCTR2000035565Phase 4Not yet recruiting
- Sponsor
- Zunyi Medical University Affiliated Hospital
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fibroblast growth factor 1 in diabetic polyneuropathy (DPN) (2 arms), sponsored by Zunyi Medical University Affiliated Hospital. Primary endpoints: Quantitative sensory testing, Toronto Clinical Neuropathy Score and 1 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
fibroblast growth factor 1
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on ChiCTR2000035565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035565.